http://www.cnr.it/ontology/cnr/individuo/prodotto/ID109041

Adipose-Tissue Insulin Resistance is a Major Metabolic Abnormality of Patients with IGT/T2DM and _ASH: Reversal with Pioglitazone Treatment (Abstract/Poster in atti di convegno)

Type

Label

Adipose-Tissue Insulin Resistance is a Major Metabolic Abnormality of Patients with IGT/T2DM and _ASH: Reversal with Pioglitazone Treatment (Abstract/Poster in atti di convegno) (literal)

Anno

Alternative label

Gastaldelli A.; Hardies J.; Belfort R.; Harrison S.; Balas B.; Defronzo R.; Brown K.; Schenker S.; Cusi K. (2007)
Adipose-Tissue Insulin Resistance is a Major Metabolic Abnormality of Patients with IGT/T2DM and _ASH: Reversal with Pioglitazone Treatment
in Annual Meeting of American Diabetes Association, Chicago
(literal)

Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#autori

Gastaldelli A.; Hardies J.; Belfort R.; Harrison S.; Balas B.; Defronzo R.; Brown K.; Schenker S.; Cusi K. (literal)

Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#volumeInCollana

Rivista

Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#note

In: Annual Meeting of American Diabetes Association (Chicago, 22-26 giugno 2007). Proceedings, pp. A40 - A40. American Diabetes Association, 2007. (literal)

Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#descrizioneSinteticaDelProdotto

Results: We have recently reported that pioglitazone (PIO) improved glucose metabolism and histology in 55 IGT/T2DM subjects with non-alcoholic steatohepatitis (NASH). Because insulin resistance (IR) and abnormal lipid metabolism are important in the development of steatosis, we examined the role of adipose tissue IR and impact of PIO in these pts who were randomized (double-blind) to PIO (45mg/d) or placebo (Pbo) for 6 months.Before and after treatment pts underwent: 1) liver biopsy; 2) measurement of liver fat content by magnetic resonance (L-MRS); 3) a double-tracer 75gOGTT to assess glucose tolerance, production (EGP) and clearance (glu disposal/plasma glu), and to estimate indexes of IR in adipose tissue (Ad-IRI=fasting plasma FFA x insulin conc [FPI]) and liver (H-IRI=EGP x FPI). 15 control subjects (CON) were also studied in the same way (except for liver biopsy).Compared to CON, NASH pts had increased FFA (739±34 vs. CON 596±44 umol/l; p0.001), impaired FFA suppression during OGTT (360±18 vs 240±19 umol/l; p0.001), severe adipose-IR (12.1±1.3 vs. 2.7±0.6 mmol/l\"mU/l, p0.0003) and low adiponectin (7.0±1.6 vs. 13.2±2.1 mg/l p0.001). L-MRS was ^3-fold higher in NASH (p0.001) and correlated positively with adipose-IR (r (literal)

Note